Clinical Trials Logo
  1. Home
  2. Biliary Tract Neoplasms
  3. NCT03875235

Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1) — TOPAZ-1  

Biliary Tract Neoplasms Clinical Trial

Official title:
A Phase III Randomized, Double-Blind Placebo Controlled, Multi-Regional, International Study of Durvalumab in Combination With Gemcitabine Plus Cisplatin Versus Placebo in Combination With Gemcitabine Plus Cisplatin for Patients With First-Line Advanced Biliary Tract Cancers

Clinical Trial Summary

Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)

Clinical Trial Description

A Phase III Randomized, Double-Blind Placebo Controlled, Multi-Regional, International Study of Durvalumab in Combination with Gemcitabine Plus Cisplatin Versus Placebo in Combination with Gemcitabine Plus Cisplatin for Patients With First-Line Advanced Biliary Tract Cancers. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03875235
Study type Interventional
Source AstraZeneca
Contact
Status Active, not recruiting
Phase Phase 3
Start date April 16, 2019
Completion date March 31, 2025
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT01950572 - Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Completed NCT03101566 - Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer Phase 2
Recruiting NCT05237193 - A Prospective Study of UCAD for Diagnosing Benign or Malignant Biliary Obstruction and Follow-up
Not yet recruiting NCT06037655 - Chemotherapy Combined With Adebrelimab and Mecapegfilgrastim in Neoadjuvant Treatment of Potentially Resectable BTC Phase 2
Recruiting NCT04584008 - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics N/A
Completed NCT00196105 - Malignant Obstruction ZILVER Against Routine Therapy (MOZART I) N/A
Completed NCT02558959 - Second-line Irinotecan and Capecitabine Versus Irinotecan for Gemcitabine and Cisplatin Refractory Biliary Tract Cancer Phase 2
Completed NCT02829918 - Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers Phase 2
Completed NCT02784353 - Clinical Outcomes of Preoperative and Postoperative Rehabilitation in the Patients With HBP Malignancy N/A
Recruiting NCT05429203 - Comparison of Duodenoscope With Single-use Distal Cover and the Conventional Reusable Duodenoscope N/A
Recruiting NCT02255669 - Fully Covered SEMS Versus Partially Covered SEMS With Anti-migration System for Malignant Distal Biliary Obstruction N/A
Completed NCT01731821 - Nonstented Stump-closed vs Duct-to-Mucosa Pancreaticojejunostomy After Pancreaticoduodenectomy Phase 3
Completed NCT00422409 - Endoscopic Stenting of Gastrointestinal Cancer N/A
Terminated NCT02900248 - CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
Recruiting NCT03063554 - EUS BD vs ERCP TP for Pancreatic Cancer N/A
Terminated NCT02615210 - Mid-Atlantic Research Group Single-Operator Cholangioscopic Assessment of Biliary Strictures N/A
Completed NCT04595058 - LAMS Choledochoduodenostomies: With or Without Coaxial Plastic Stent N/A
Recruiting NCT04856761 - A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection
Recruiting NCT03427242 - Apatinib for Advanced Biliary Carcinoma Phase 2
Recruiting NCT05615818 - Personalized Medicine for Advanced Biliary Cancer Patients Phase 3